Find a clinical trial

Please use one or more of the field below to begin your search.

614 Results

Located at

With doctor

For patient age

All clinical trials

  • Protocol number: 00000441

    Title: Same-Day Discharge after Nipple Sparing or Skin Sparing Mastectomy with Breast Reconstruction

  • Protocol number: 015-00-E7080-G000-321

    A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) plus Lenvatinib (E7080/MK-7902) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic HER2 Negative Gastric/Gastroesophageal Junction Adenocarcinoma (LEAP-015)

  • Protocol number: 10129-NCT03212274

    A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

  • Protocol number: 19-047-NCT04139902

    RANDOMIZED PHASE II NEOADJUVANT STUDY OF PD-1 INHIBITOR DOSTARLIMAB (TSR-042) VS. COMBINATION OF TIM-3 INHIBITOR TSR-022 AND PD-1 INHIBITOR DOSTARLIMAB (TSR-042) IN RESECTABLE STAGE III OR OLIGOMETASTATIC STAGE IV MELANOMA (NEO-MEL-T)

  • Protocol number: 20-041-NCP-NCT04264702

    BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

  • Protocol number: 2008-363

    Older Breast Cancer Patients: Risk for Cognitive Decline

  • Protocol number: 2010-611

    Decision Making Interventions for Women Receiving Uninformative BRCA1/2 Test Results or Positive BRCA1/2 Results

  • Protocol number: 2013-0496

    A cross-over pilot study of the effect of amiloride compared to triamterene on proteinuria in patients with proteinuric kidney disease

  • Protocol number: 2014-0755

    Identifying children with diabetes type 1 at high risk for cardiovascular disease

  • Protocol number: 2014-1041

    Circulating Free DNA Molecular Tumor Response to Definitive Treatment

  • Protocol number: 2015-1008

    Evolving Model of Cancer Susceptibility Testing: Clinical Decisions and Outcomes

  • Protocol number: 2015-1243-NCT02685631

    Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study

  • Protocol number: 2016-0220

    Molecular Epidemiology of Oxidative Stress and Related Cancers in Black Women

  • Protocol number: 2016-0435

    Acupressure Intervention to Improve Fatigue and Physical Functioning of Chinese Immigrant Breast Cancer Survivors

  • Protocol number: 2016-0651

    Integrating Evidence-Based Smoking Cessation Interventions Into Lung Cancer Screening Programs: A Randomized Trial

  • Protocol number: 2016-1162

    The Genetic Education for Men (GEM) Trial: Web-Based Genetic Education vs. Standard Care in Men From Hereditary Cancer Families

  • Protocol number: 2016-1407

    Web-Based Communication Education for Breast Cancer Survivorship Care

  • Protocol number: 2017-0201

    Scleroderma Lung Study III (SLS III): Combining the anti‐fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma‐ related interstitial lung disease

  • Protocol number: 2017-0440

    An Open Label, Phase I study to evaluate the impact of low doses of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Huntington’s Disease

  • Protocol number: 2017-0478

    STEPs to Blood Pressure Reduction. A Randomized Clinical Trial of the Stroke Transitions, Education, and Prevention Clinic Versus Usual Care for Post-Stroke Blood Pressure Reduction

  • Protocol number: 2017-0524-INT

    Testing an Intelligent Tutoring System Intervention to Enhance Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer.

  • Protocol number: 2017-0690

    MedStar Georgetown Transplant Institute Biorepository

  • Protocol number: 2017-0700-NCT03685461

    Intra- and Post-Operative Measures of Auditory Function

  • Protocol number: 2017-0838/GR412607

    Optimizing Bilateral and Single-Sided Deafness Cochlear Implants for Functioning in Complex Auditory Environments

  • Protocol number: 2017-0961

    MRI evaluation of recurrent disk herniation without post-contrast imaging using 3D T2 SPACE

  • Protocol number: 2017-1041-NCT03104517

    CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence

  • Protocol number: 2017-1314

    Protocol I7S-MC-HBEH Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson’s Disease Dementia (PDD)

  • Protocol number: 2017-1316

    Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase I/II Multicenter, Randomized, Double Blinded, Safety Study (BRAVOS)

  • Protocol number: 2017-1347-NCT03325790

    A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease

  • Protocol number: 2017-1366

    Long Term Follow Up Patients with Follicular Lymphoma

  • Protocol number: 2017-1393

    A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE

  • Protocol number: 2018-0114

    A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System

  • Protocol number: 2018-0191

    Investigation of the Effects of Radioactive Iodine on the Salivary Glands

  • Protocol number: 2018-0304-NCT03838926

    Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

  • Protocol number: 2018-0439

    A Randomized Trial of Proactive Outreach and Streamlined Genetic Education in BRCA Families

  • Protocol number: 2018-0440-NCT02570308

    A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma

  • Protocol number: 2018-0480

    A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPLTmPRIME for the Treatment of Chronic Venous Leg Ulcers

  • Protocol number: 2018-0738-NCT02911571

    Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients

  • Protocol number: 2018-0808

    Hydromechanical Cleansing With V.A.C. VERAFLO CLEANSE CHOICETM Dressing and NPWTi-d vs. Collagenase Ointment in the Management of Pressure Ulcers/Injuries (ACCELERATE Trial)

  • Protocol number: 2018-0979

    A Multi-center, Patient Outcome Registry for a Hydroxyapatite infused PEEK Interbody Fusion Device

  • Protocol number: 2018-1092

    A Retrospective Chart Review and analysis of oncologic patients undergoing curative or palliative treatments within the MedStar Georegetown University Hospital Interventional Radiology Department

  • Protocol number: 2018-173

    MedStar Plastic Reconstructive Surgery Outcomes Registry

  • Protocol number: 2018-242

    Outcomes Evaluation of the Medial Femoral Trochlea Flap for Reconstruction of the Scaphoid and Lunate

  • Protocol number: 2019-1

    A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients

  • Protocol number: 20190009

    A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

  • Protocol number: 20190294

    A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC)

  • Protocol number: 208090

    A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed

  • Protocol number: 221AD304

    A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (EMBARK)

  • Protocol number: 4020-01-001-NCT02817633

    A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)

  • Protocol number: 54767414MMY3021

    A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

  • Protocol number: 61186372NSC3001

    A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Protocol number: A011202-NCT01901094

    A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

  • Protocol number: A011801-COMPASSHER-NCT04457596

    The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

  • Protocol number: A021703-SOLARIS-NCT04094688

    Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

  • Protocol number: A021806-NCT04340141

    A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

  • Protocol number: A031102-NCT02375204

    A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

  • Protocol number: A031702-NCT03866382

    A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

  • Protocol number: A031704-PDIGREE-NCT0379316

    A031704, PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab in metastatic untreated REnal Cell CancEr [PDIGREE]

  • Protocol number: A041703-NCT03739814

    A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

  • Protocol number: A071801-NCT04114981

    PHASE III TRIAL OF POST-SURGICAL SINGLE FRACTION STEREOTACTIC RADIOSURGERY (SRS) COMPARED WITH FRACTIONATED SRS (FSRS) FOR RESECTED METASTATIC BRAIN DISEASE

  • Protocol number: A081801-NCT04267848

    Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study

  • Protocol number: A231601CD-OPTI-SURGNCT03857620

    Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)

  • Protocol number: AALL1131

    Phase III Randomized Trial for Newly Diagnosed High Risk B-Precursor Acute Lymphoblastic Leukemia Testing Clofarabine in the Very High Risk Stratum

  • Protocol number: AALL1621-NCT02981628

    Protocol AALL1621 A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

  • Protocol number: AALL1631-NCT03007147

    International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

  • Protocol number: AALL1731-NCT03914625

    A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

  • Protocol number: AALL1732-NCT03959085

    A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

  • Protocol number: AAML1531-NCT02521493

    AAML1531 Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

  • Protocol number: AAML1831-NCT04293562

    A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.

  • Protocol number: ABOLISH

    INTERNATIONAL, MULTICENTRE, OBSERVATIONAL, PROSPECTIVE, LONGITUDINAL STUDY TO ASSESS THE EFFECTIVENESS OF ABOBONT-A INJECTIONS FOR ADULT LOWER LIMB SPASTICITY IN A REAL LIFE COHORT (ABOLISH)

  • Protocol number: ABTR04B1-NCT00898755

    ABTR04B1 Establishing Continuous Cell Lines and xenografts from Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies

  • Protocol number: ACCRU-GI-1611-NCT03765736

    COLOMATE: COlorectal Cancer Liquid BiOpsy Screening Protocol for Molecularly Assigned ThErapy

  • Protocol number: ACCRU-GI-1623-NCT03992456

    PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy after Progression on Anti-EGFR Therapy in Patients with Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

  • Protocol number: ACCRU-GI-1701

    A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients with Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

  • Protocol number: ACCRU-GI-1809-NCT04117945

    A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR monoclonal antibody therapy Versus the Reverse Sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan (REVERCE II)

  • Protocol number: ACNS1422-NCT02724579

    Protocol ACNS1422 A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

  • Protocol number: ACNS1721-NCT03581292

    A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutation

  • Protocol number: ACNS1723-NCT03919071

    A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

  • Protocol number: ACNS1831-NCT03871257

    A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

  • Protocol number: ACNS1833-NCT04166409

    A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

  • Protocol number: ACURATE-NCT03735667

    Transcatheter Replacement of Stenotic Aortic Valve through Implantation of ACURATE in Subjects InDicatEd for TAVR

  • Protocol number: ADAMAS301-NCT03436199

    A 3-ARM, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT

  • Protocol number: ADAP-008-NCT04545333

    Real World Observational Study using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The Watch Registry

  • Protocol number: ADNI3-NCT02854033

    Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3)

  • Protocol number: ADSAMTMS303-NCT03567057

    A MULTICENTER, OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT

  • Protocol number: ADVL1521-NCT03190915

    A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093)in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

  • Protocol number: ADVL1622-NCT02867592

    Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

  • Protocol number: ADVL1823-NCT03834961

    Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemia

  • Protocol number: ADVL18P1-NCT04203316

    Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

  • Protocol number: AFFINITY-NCT03222973

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

  • Protocol number: AGAREGISTRY

    Fecal Microbiota Transplant National Registry

  • Protocol number: AGCT1531-NCT03067181

    A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

  • Protocol number: AGCT1532-NCT02582697

    Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

  • Protocol number: AGN-151607-NCT02617069

    A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A (AGN-151607) Injections into the Epicardial Fat Pads to Prevent Post-Operative Atrial Fibrillation in Patients Undergoing Open-Chest Cardiac Surgery

  • Protocol number: AGT-HC168

    Phase I Study to Evaluate the Safety of Genetically Modified, Autologous T Cells in Participants with HIV that is Well-Controlled on Antiretroviral Therapy

  • Protocol number: AHEAD3-45

    AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer s Disease and Intermediate Amyloid (A3 Trial)

  • Protocol number: AHEP1531-NCT03533582

    Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

  • Protocol number: AIC316-03-II-01

    A randomized, open label, multi center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised adults (PRIOH-1)

  • Protocol number: AIMPOWER-NCT04191330

    Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors

  • Protocol number: AL42478

    An Expanded Access, Single-Arm, Multicenter Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

  • Protocol number: ALCOHOLICHEPATITIS

    Outcomes of Alcoholic Hepatitis and Alcohol Cirrhosis Patients after Liver Transplant

  • Protocol number: ALIGN-AR-NCT04415047

    A Study to Assess Safety and Probable Benefit of the Transfemoral JenaValve Pericardial TAVR System in the Treatment of High Surgical Risk Patients with Symptomatic, Severe Aortic Regurgitation (AR)

  • Protocol number: ALKS4230-001-NCT02799095

    A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1

  • Protocol number: ALTAVALVE-NCT03997305

    AltaValve Early Feasibility Study Protocol

  • Protocol number: ALTE05N1

    Umbrella Long-Term Follow-Up Protocol

  • Protocol number: ALTE07C1

    Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

  • Protocol number: ALTE1631-NCT03223753

    A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Cancer

  • Protocol number: ALTE16C1

    Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma

  • Protocol number: ALTE2031-NCT04089358

    StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors

  • Protocol number: ALXN1210COV305

    A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

  • Protocol number: ALXN1210MG306-NCT03920293

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

  • Protocol number: AMBULATE-SDD-RETRO

    AMBULATE Same Day Discharge (SDD) Retrospective Registry Protocol

  • Protocol number: AMG423-SHAH-NCT02929329

    Registrational Study to Treat Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

  • Protocol number: AML-PROSPECTIVE-STUDY00000298

    A Pilot Study to Evaluate Physical Function and Fatigue in Patients with Acute Myeloid Leukemia Single Center Prospective Cohort Study

  • Protocol number: AML-RETROSPECTIVE- STUDY00001361

    A center-based chart review study to assess treatment outcomes of venetoclax for the treatment of acute myeloid leukemia (AML)

  • Protocol number: AMPLATZER-PFO-NCT03309332

    AMPLATZER PFO Occluder Post Approval Study (PFO PAS)

  • Protocol number: ANBL00B1

    Neuroblastoma Biology Studies

  • Protocol number: ANBL1232-NCT02176967

    Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

  • Protocol number: ANX005-HD-001

    A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects with, or at Risk for, Manifest Huntington’s Disease

  • Protocol number: APEC14B1

    APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

  • Protocol number: APEC1621I-NCT03526250

    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

  • Protocol number: APEC1621SC-NCT03155620

    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

  • Protocol number: APOL-1

    Integrating a Culturally Competent APOL1 Genetic Testing Program into Living Donor Evaluation

  • Protocol number: APOLLO-NCT03242642

    Transcatheter Mitral Valve Replacement with the Medtronic Intrepid TMVR System in patients with severe symptomatic mitral regurgitation APOLLO Trial

  • Protocol number: APPRAISEATP-NCT02923726

    Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP -APPRAISE

  • Protocol number: APX005M-006-NCT03165994

    A Phase 2 Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

  • Protocol number: ARCADIA-NCT03192215-NRH

    AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)

  • Protocol number: AREN03B2

    Renal Tumors Classification, Biology and Banking Study

  • Protocol number: ARGX-113-1803

    A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia

  • Protocol number: ARGX113-1801

    A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia

  • Protocol number: ARIES-HM3-NCT04069156

    Antiplatelet Removal and HemocompatIbility EventS with the HeartMate 3 Pump

  • Protocol number: ARST1431-NCT02567435

    A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

  • Protocol number: ARST1921-NCT04195399

    ARST1921 A Safety, Pharmacokinetic and Efficacy Study of a γ-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors

  • Protocol number: ARTESIA-NCT01938248

    Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial fibrillation

  • Protocol number: ARTHREX-NCTNA

    ACL Repair with Internal Brace Augmentation

  • Protocol number: ASAPTOO-SHA-NCT02928497

    Assessment of the WATCHMANTM Device in Patients Unsuitable for Oral Anticoagulation ASAP-TOO

  • Protocol number: ATA129-EBV-302-NCT03394365

    Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

  • Protocol number: ATRC-101-A01

    A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies

  • Protocol number: ATRI-004

    In-Clinic Trial-Ready Cohort (TRC-PAD)

  • Protocol number: AUGMENT-LTS-NCT03998137

    A Prospective, Controlled, Multi-Center, Post-Approval Trial to Evaluate the Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Foot and Ankle Fusions

  • Protocol number: AURORAUS-NCT03737695

    AURORA US: PROSPECTIVE BIOSPECIMEN REPOSITORY IN METASTATIC BREAST CANCER

  • Protocol number: B-60-NCT04622319

    A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY (T-DXd vs. T-DM1 in high-risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy)

  • Protocol number: BAN2401-G000-301

    A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer s Disease.

  • Protocol number: BBI-20201001-NCT04278144

    Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2- Expressing Solid Tumors

  • Protocol number: BEAR

    Bridge-Enhanced ACL Repair (BEAR)

  • Protocol number: BESTREGISTRY-NCT04191746

    BEST-Registry

  • Protocol number: BHV3500-203

    BHV3500-203: Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Vazegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients with COVID-19 Requiring Supplemental Oxygen

  • Protocol number: BIODESIX

    A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Classifier in Incidentally Discovered Low to Moderate Risk Lung Nodules

  • Protocol number: BIOREC

    Biomarkers of Stroke Recovery Study

  • Protocol number: BIOTIN

    Effect of Biotin in thyroid laboratory exams

  • Protocol number: BIVV009-04

    A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion (Cadenza)

  • Protocol number: BLU-667-1101-NCT03037385

    A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

  • Protocol number: BN40955-STUDY00001535

    AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON S DISEASE

  • Protocol number: BOSUTINIB-WI231696

    A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and HER2 Negative (HR+ HER2-) Breast Cancer Refractory to an Aromatase Inhibitor and a CDK4/6 Inhibitor (ASPIRE - WI231696)

  • Protocol number: BQ5-NCT05044507

    The efficacy of a frequency-tuned electromagnetic field treatment in facilitating the recovery of subacute ischemic stroke patients a pivotal study

  • Protocol number: C-935788-057

    A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

  • Protocol number: C-935788-058

    A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

  • Protocol number: C3441052-NCT04821622

    TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

  • Protocol number: CA209-7DX-MWHC

    A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)

  • Protocol number: CA209-9DW-NCT04039607

    A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma

  • Protocol number: CA20976K-NCT04099251

    A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma

  • Protocol number: CA2098TT-NCT03899155

    Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab

  • Protocol number: CA42481

    A Phase II, Open-Label, Randomized, Multicenter Study To Investigate the Pharmacodynamics, Pharmacokinetics, Safety and efficacy of 8mg/kg or 4mg/kg Intravenous Tocilizumab in Patients with moderate to severe COVID-19 Pneumonia

  • Protocol number: CAD

    Hand arterial calcification as a predictor for subclinical coronary artery disease using coronary artery calcium scoring.

  • Protocol number: CAD-DECISIONAID

    Shared Decision Making in the Prevention and Management of Cardiovascular Disease

  • Protocol number: CARDIAMP-NCT02438306

    Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy in Patients With Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)

  • Protocol number: CARDUS-HANDHELD

    Handheld Cardiac Ultrasound in Resident Assessment of Left Ventricular Ejection Fraction in Outpatients

  • Protocol number: CAREGIVERBUDDY

    Caregiver Buddy: Leveraging Standards to Help Cancer Caregivers and Clinicians

  • Protocol number: CAREPROMPTER

    Establishing the Feasibility of a Nurse-Triage Patient-Engagement Tool to Improve Outpatient Symptom Management of Patients on Regorafenib

  • Protocol number: CARES

    Multi-level interventions to manage co-morbidities among Black breast and prostate cancer patients

  • Protocol number: CATALYST-NCT04226547

    Clinical trial of atrial fibrillation patients comparing left atrial appendage occlusion therapy to non-vitamin K antagonist oral anticoagulants

  • Protocol number: CCTGMA39-NCT03488693

    TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

  • Protocol number: CGX1321-101-NCT02675946

    A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects With Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Gastrointestinal Tumors

  • Protocol number: CHAMPION-AF

    WATCHMAN FLX versus NOAC for EMbolic ProtectION in the Management of Patients with Non-Valvular Atrial Fibrillation

  • Protocol number: CHEVAS-AAA-NCT04252573

    Prospective, multicenter, non-randomized study with consecutive, eligible subject enrollment at each site, for the evaluation of the ChEVAS System for Endovascular Repair of Paravisceral, Juxtarenal, and Pararenal Abdominal Aortic Aneurysms.

  • Protocol number: CHIEF-HF

    Randomized, double-blind, placebo-controlled, decentralized, virtual, interventional, superiority study conducted in the United States (US) in participants with symptomatic HF (stratified by heart failure with reduced ejection fraction [HFrEF] and heart failure with preserved ejection fraction [HFpEF]) to examine the improvement in the KCCQ TSS after 3 months of treatment with canagliflozin 100 mg or placebo.

  • Protocol number: CHIMES-NCT04377555

    AN OPEN-LABEL, MULTICENTER STUDY TO ASSESS DISEASE ACTIVITY AND BIOMARKERS OF NEURONAL DAMAGE IN MINORITY PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RECEIVING TREATMENT WITH OCRELIZUMAB

  • Protocol number: CINC280A2201-NCT02414139

    A Phase II, Multicenter Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC)(Geometry Mono-1)

  • Protocol number: CITR

    Collaborative Islet Transplant Registry

  • Protocol number: CLARITI-NCT04304105

    CLariTI Natural progression of High-Risk Chronic Limb-Threatening Ischemia

  • Protocol number: CLASP-IID-NCT03706833

    Edwards PASCAL TrAnScatheter Mitral Valve RePair System Pivotal Clinical Trial (CLASP IID): A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Mitral Valve Repair System compared to Abbott MitraClip in patients with degenerative mitral regurgitation (DMR).

  • Protocol number: CLEAR-SYNERGY-NCT03048825

    Colchicine and Spironolactone in Patients With STEMI / SYNERGY Stent Registry (CLEAR-SYNERGY)

  • Protocol number: CLOUT-NCT03575364

    ClotTriever Outcomes (CLOUT) Registry

  • Protocol number: CLR1806-NCT03655236

    A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF K0706 IN SUBJECTS WITH EARLY PARKINSON S DISEASE

  • Protocol number: CMRI-DIASTOLIC

    Diastolic Dysfunction on Cardiac MRI

  • Protocol number: CNMC-

    Bio-repository for Cells, Tissue, Blood, Urine and DNA

  • Protocol number: COMET-NCT02926911

    COMET-Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

  • Protocol number: COMFORTSAFE

    Improving Patient Outcomes Using Multimodal Perioperative Pain Management:The ComfortSafe Program

  • Protocol number: COMPARTMENTSYNDROME

    Non-Invasive Observational Study of Extremity Compartment Syndrome Using Philips Ultrasound Shear Wave Elastography and Micro-vascular Flow Imaging

  • Protocol number: CONFIDENCE-NCT02657707

    CONFIDENCE TRIAL: Carotid Stent Trial to Evaluate the Safety and Efficacy of the Roadsaver Stent Used in Conjunction with the Nanoparasol® Embolic Protection System for Patients at Increased Risk for Adverse Events from Carotid Endarterectomy

  • Protocol number: CONNECT-HF-NCT03035474

    CARE OPTIMIZATION THROUGH PATIENT AND HOSPITAL ENGAGEMENT CLINICAL TRIAL FOR HEART FAILURE CONNECT-HF

  • Protocol number: COOLSTAT-NCT03360656

    Transnasal Induction of Normothermia in NCCU Fever Patients

  • Protocol number: CORCINCH-NCT03533517

    Randomized Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)

  • Protocol number: COREVNS-NCT03529045

    Comprehensive Outcomes Registry in Subjects with Epilspsy Treated with Vagus Nerve Stimulation Therapy

  • Protocol number: CORMATRIX-NCT02397668

    CORMATRIX® COR™ TRICUSPID ECM® VALVE REPLACEMENT SAFETY AND EARLY FEASIBILITY STUDY

  • Protocol number: COVID-ACTIV

    Randomized Master Protocol for Immune Modulators for Treating COVID-19

  • Protocol number: COVID-ARC-19-NCT04401449

    Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVID ARC 19)

  • Protocol number: COVID-ATYR

    A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related To SARS-CoV-2 Infection (COVID-19)

  • Protocol number: COVID-BEIGENE

    A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress.

  • Protocol number: COVID-BELNACASAN

    Safety, tolerability, and treatment effect of belnacasan in patients with COVID-19: A Proof of concept, randomized, double-blind, placebo-controlled trial of orally administered belnacasan tablets for the treatment of mild to moderate COVID-19

  • Protocol number: COVID-BLOOD-DONATION

    Screening of COVID-19 Patients for Convalescence Serum Donation

  • Protocol number: COVID-CALAVI

    A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19

  • Protocol number: COVID-CALYPSO

    COVID-19 associated Lymphopenia Pathogenesis Study in Blood

  • Protocol number: COVID-CHARTREVIEW

    A Multi-center, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults with Severe COVID-19

  • Protocol number: COVID-CSSC004

    Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized, Double-Blind, Controlled, Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune) Plasma Among Outpatients with Symptomatic COVID-19.

  • Protocol number: COVID-HGEN003-06

    A Phase 3, Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients with COVID-19 Pneumonia

  • Protocol number: COVID-LUNGULTRASOUND

    Use of Point of Care Ultrasound to Collect Lung Images in Suspected COVID-19 Positive Subjects

  • Protocol number: COVID-PACT-NCT04409834

    A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients

  • Protocol number: COVID-PASSITON

    Passive Immunity Trial for Our Nation (PassItOn)

  • Protocol number: COVID-SORRENTO

    A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF THE SAFETY AND EFFICACY OF STI-5656 (ABIVERTINIB MALEATE) IN SUBJECTS HOSPITALIZED DUE TO COVID-19.

  • Protocol number: CP-MGD006-01-NCT02152956

    A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome

  • Protocol number: CP201901-NCT04066023

    Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches

  • Protocol number: CPDR001J2201-NCT03484923

    A Randomized, Open-Label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma

  • Protocol number: CR108401-NCT03390504

    A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

  • Protocol number: CX-839-011-NCT03875313

    A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors

  • Protocol number: D7980C00003-NCT04522323

    A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma

  • Protocol number: D8220R00004-NCT03816683

    Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents

  • Protocol number: D9103C00001-PACIFIC4-WHC

    A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

  • Protocol number: D910FC00001-NCT04078152

    An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)

  • Protocol number: D91DC00001-EMERALD-2

    A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

  • Protocol number: D933GC00001-EMERALD-1-NCT03778

    A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)

  • Protocol number: DCM-CMR-STUDY

    Dilated Cardiomyopathy (DCM) Research Project Sub-study: Advanced Procedures Sub-Study

  • Protocol number: DCP-002

    Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Colon, Kidney, Liver, Multiple Myeloma, and Prostate among Racially and Ethnically Diverse Populations

  • Protocol number: DEBIO1143-106-NCT04122625

    A Phase-Ib Dose-Finding Study of the SMAC Mimetic Debio 1143 When Given in Combination With the Anti-PD-L1 Antibody Avelumab to Patients With Advanced Solid Malignancies and, in an Expansion Cohort, to Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

  • Protocol number: DERMACELL

    A Randomized, Prospective Trial Comparing the Clinical Outcomes for DermACELL® Compared with Integra® Bilayer Wound Matrix

  • Protocol number: DETOURII-NCT03119233

    DETOURII

  • Protocol number: DFU-GSH

    Randomized Clinical Trial to Compare Transforming Powder and Standard of Care Dressing Therapies to Heal Diabetic Foot Ulcers

  • Protocol number: DFU-WHC

    Randomized Clinical Trial to Compare Transforming Powder and Standard of Care Dressing Therapies to Heal Diabetic Foot Ulcers

  • Protocol number: DIS-DMTMS

    Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

  • Protocol number: DISCOMS-NCT03073600

    Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

  • Protocol number: DISRUPTPAD-NCT02923193

    Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)

  • Protocol number: DLS-HCV-MUMH-NCTNA

    The collection of biological specimens with comparison data from subjects that will be catalogued in a biorepository for research

  • Protocol number: DLS-HCV-MWHC-NCTNA

    The collection of biological specimens with comparison data from subjects that will be catalogued in a biorepository for research..

  • Protocol number: DOD-ADNI-NCT01687153

    Effects of traumatic brain injury and post traumatic stress disorder   on Alzheimer’s disease (AD) in Veterans using ADNI (DOD ADNI)

  • Protocol number: DURECTAH

    A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis

  • Protocol number: E4512-NCT02201992

    A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

  • Protocol number: EA1151-TMIST-NCT03233191

    Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EA 1151

  • Protocol number: EA6141-NCT02339571

    Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

  • Protocol number: EA6174-NCT03712605

    STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

  • Protocol number: EA6192

    A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

  • Protocol number: EARLYTAVR-NCT03042104

    Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis: EARLY TAVR trial

  • Protocol number: EASESBS1-NCT03690206

    A PHASE 3, INTERNATIONAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF GLEPAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME (SBS)

  • Protocol number: EASESBS2EXT-NCT03905707

    A Double-Blind Phase 3 Extension Trial Assessing the Long-Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel

  • Protocol number: ECG-002

    This is a non-invasive, 2-part, multi-center study. The purpose of this study is two-fold: 1) To validate a rhythm classification algorithm and its ability to detect and classify heart rhythms into one of two categories (SR or AF) using a single Lead I ECG strip. 2) To demonstrate that the SUT produces a waveform that provides information that is clinically equivalent to the gold standard.

  • Protocol number: ECGBELT-NCT03504020

    ECG Belt for CRT Response

  • Protocol number: EEG-ENDO

    Investigation of pre-operative electroencephalogram (EEG) based central sensitivity measurements on surgical outcomes for patients undergoing operative laparoscopy for endometriosis diagnosis and treatment.

  • Protocol number: EKO-HOME-NCT04404452

    Heart Failure Monitoring with Eko Electronic Stethoscopes

  • Protocol number: EKO-LOWEF-NCT04400435

    Detection of Reduced Left Ventricular Ejection Fraction and Atrial Arrhythmias with Single Lead ECG using Artificial Intelligence

  • Protocol number: ELVCAP-001-01-NCT04383210

    A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

  • Protocol number: EMPACT-MI

    EMPACT-MI: A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction

  • Protocol number: EMPAKIDNEY-NCT03594110

    A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease

  • Protocol number: EMPOWER-NCT04598698

    EMPOWER: Endometriosis diagnosis using MicroRNA: PrOspective study in Women to allow Early disease Recognition

  • Protocol number: ENCIRCLE-NCT04153292

    The ENCIRCLE Trial SAPIEN M3 System TransCatheter MItral Valve ReplaCement via TransseptaL AccEss

  • Protocol number: ENDURANCE-NCT01966458

    HeartWare HVAD- HW004A Endurance

  • Protocol number: ENDURANCE-RUNNERS

    Atrial size, function and fitness level among endurance runners with known paroxysmal atrial fibrillation

  • Protocol number: EPROMPT-NCT03423459

    CoreValve Evolut PRO prospective registry

  • Protocol number: ERYASPASE

    A Phase I Dose Escalation Study of Eryaspase in Combination With Modified FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

  • Protocol number: ES201601-NCTNA

    Blood Sample Collection in Subjects with Pulmonary Nodules or CT Suspicion of Lung Cancer

  • Protocol number: ESR-18-13870

    A Phase II Trial of Durvalumab (MEDI4736) in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

  • Protocol number: ETCTN-10009-NCT02936752

    A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure

  • Protocol number: ETCTN-10315-NCT04079712

    A Phase II Clinical Trial of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas

  • Protocol number: ETCTN10166-NCT03600701

    A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

  • Protocol number: ETCTN10266-NCT03965689

    A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy

  • Protocol number: ETCTN10334

    BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy

  • Protocol number: ETCTN10399-NCT04631029

    A Phase 1 Study of Entinostat in Combination with Atezolizumab / Carboplatin / Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer

  • Protocol number: ETCTN9673-NCT02314169

    A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal

  • Protocol number: ETCTN9898-NCT02496663

    A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

  • Protocol number: EV-ICD

    ExtraVascular Implantable Cardioverter Defibrillator (EV ICD) Pivotal Study

  • Protocol number: EVAULT

    Long-term outcomes following vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study (eVAULT)

  • Protocol number: EXPAREL-NCT03504865

    Single-Blinded, Randomized Assessment of Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo

  • Protocol number: EXT00000206-PRELUDE

    A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy

  • Protocol number: FDAEXPLANT

    A Prospective Study Evaluating Reverse Total Shoulder Arthroplasty (rTSA) Device Durability and Performance.

  • Protocol number: FEVAR-NCT04526938

    Clinical Outcomes, Radiation Dosage, and Quality of Life in Patients Treated with Fenestrated Stent Grafts for Complex Thoracoabdominal and Abdominal Aortic Aneurysms, and Thoracoabdominal Aortic Aneurysms secondary to Aortic Dissections

  • Protocol number: FFP

    Identification of Mechanisms Underlying the Effects of Plasma Inclusive Resuscitation in Major Thermal Injury on Hemostasis and Vascular Homeostasis

  • Protocol number: FLX475-02-NCT03674567

    Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

  • Protocol number: FOCUS-NN9535-4352-NCT03811561

    FOCUS

  • Protocol number: FREEDOM--NCT03995901

    A 5-year, randomized, controlled, multi-center study to assess the safety and efficacy of FCR001 cell-based therapy relative to tacrolimus and mycophenolate mofetil in de novo living donor renal transplant recipients and safety in FCR001 donors

  • Protocol number: G1T28-207-NCT04607668

    A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer

  • Protocol number: G1T28-208

    A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)

  • Protocol number: G1T28-209-NCT04887831

    .A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)

  • Protocol number: GAM10-10

    Efficacy and safety of Octagam 10% therapy in COVID-19 patients with severe disease progression

  • Protocol number: GENERATION1-NCT02565511

    A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.

  • Protocol number: GENMED-FEVER-MWHC

    The collection of biological specimens with companion data from subjects that will be catalogued in a biorepository for research

  • Protocol number: GI19-405-NCT04541173

    A Randomized Phase II Study Evaluating the combination of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)

  • Protocol number: GO39733-NCT03289962

    A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors

  • Protocol number: GO40515-NCT03677141

    A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

  • Protocol number: GO41767-NCT04256421

    A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  • Protocol number: GO42216

    A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORPHEUS-LIVER)

  • Protocol number: GO42501-NCT04832854

    A PHASE II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF NEOADJUVANT AND ADJUVANT TIRAGOLUMAB PLUS ATEZOLIZUMAB, WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY, IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED RESECTABLE STAGE II, IIIA, OR SELECT IIIB NONSMALL CELL LUNG CANCER

  • Protocol number: GORETAG-NCT02777528

    Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta

  • Protocol number: GORETAMBE-NCT03728985

    Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

  • Protocol number: GP-88

    Serum GP-88 Levels in Metastatic Breast Cancer patients: A Prospective Blood Sampling Trial

  • Protocol number: GS-US-200-4334

    A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV

  • Protocol number: GS-US-420-3902

    A Phase 1b Randomized, Blinded, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-9722 in Virologically suppressed HIV-1 infected subjects on ART

  • Protocol number: GS-US-540-5912-COVID-KIDNEY

    A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19

  • Protocol number: GU16-260-NCT03117309

    Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260

  • Protocol number: GUARDIAN-REGISTRY

    GUARDIAN

  • Protocol number: GWSC19216

    An Observational Clinical Study of Patients with Spasticity Associated with Spinal Cord Injury

  • Protocol number: HA-PEEK

    A Multi-center, Patient Outcome Registry for a Hydroxyapatite infused PEEK Interbody Fusion Device

  • Protocol number: HALO-107-101-NCT02563548

    HALO-107-101: A Phase 1b, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan High Solid Tumors

  • Protocol number: HARP-NCT02905357

    Heart Attack Research Program (HARP)

  • Protocol number: HBVFB

    Impact of Recent Immigration on Delays in Care Delivery among Foreign-Born with Chronic Hepatitis B Infection

  • Protocol number: HE-OLAPARIB-PEMBRO-NCT04306367

    A Phase II, Single-arm, Multi-Center Study of Combination Pembrolizumab and Olaparib in the Treatment of Patients with Advanced Cholangiocarcinoma

  • Protocol number: HEM-PWRV1US

    HEM-POWR: Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A

  • Protocol number: HEPATICADENOMAS

    Outcomes of patients with Benign Liver Lesions

  • Protocol number: HEPE-NCT02190253

    Seroprevalence of Hepatitis E in Organ Transplant subjects

  • Protocol number: HIALIVER-NCT03734393

    HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients

  • Protocol number: HM3-SWIFT-NCT04548128

    Implantation of the HeartMate 3 in Subjects with Heart Failure using Surgical Techniques Other Than Full Median Sternotomy

  • Protocol number: HP-00081403-NCT03652428

    Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer

  • Protocol number: I-SPY2-NCT01042379

    I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

  • Protocol number: I5T-MC-AACI

    Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

  • Protocol number: I8F-MC-GPGN

    The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)

  • Protocol number: I8F-MC-GPHD

    Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly versus Insulin Lispro (U100) Three Times Daily in Participants with Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) with or without Metformin (SURPASS-6)

  • Protocol number: I8F-MC-GPHN

    Efficacy and Safety of Tirzepatide Once Weekly versus Placebo for Maintenance of Weight Loss in Participants without Type 2 Diabetes Who Have Obesity or Are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial(SURMOUNT-4)

  • Protocol number: IDORSIA

    Multi-center, blinded, randomized, PaRallEl-group, Phase 3 study with aproCItentan in Subjects with ResIstant HypertensiON (RHT)

  • Protocol number: IMMU-132-13-NCT04527991

    A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer

  • Protocol number: IMPROVE-NCT04221815

    IMPact on Revascularization Outcomes of intraVascular ultrasound guided treatment of complex lesions and Economic impact (IMPROVE)

  • Protocol number: INCB050465-206

    A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

  • Protocol number: INCB18424-369

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19–Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

  • Protocol number: INDUCE-3-209229-NCT04128696

    A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Protocol number: INF-04-NCT04094818

    HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis (SEPSIS-SHIELD)

  • Protocol number: INFORMEXTENDED

    Inform Extended

  • Protocol number: INS1007-301

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis The ASPEN Study

  • Protocol number: INSIGHT014-WHC

    A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19

  • Protocol number: INSIGHT015-WHC

    A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome Associated with COVID-19

  • Protocol number: INSMED312-NCT02628600

    An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment

  • Protocol number: INTEGRA2017-0908

    The Relationship Between Bacterial Load and the Clinical Outcomes for Integra in Operative Wounds

  • Protocol number: INTRAVESICAL-LACTOBACILLUS

    Intravesical Lactobacillus for Urinary Symptoms Among People with NLUTD Who Use Indwelling Catheters.

  • Protocol number: INVIVO-SKMICRO

    In vivo evaluation of aging-dependent skin microvascular function in HIV infected individuals

  • Protocol number: IO-FDG-MONITOR

    Pilot Study of Serial 18F-FDG Uptake Assessment for Prediction of Anti-PD-1 Therapy Response and Progression Free Survival in Patients with Advanced Melanoma

  • Protocol number: ION-682884-CS2

    A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  • Protocol number: ION-682884-CS3

    A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  • Protocol number: IORT-NCT03561454

    A Registry of Intra-Operative Radiation Therapy (IORT) Patients

  • Protocol number: IOV-COM-202-NCT03645928

    A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

  • Protocol number: ISIS-757456-CS5

    A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production, Administered Subcutaneously over 12 Weeks in Patients with Chronic Heart Failure with Reduced Ejection Fraction

  • Protocol number: ISPYCOVID

    I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients

  • Protocol number: IST83-NCT04091750

    Phase II Study of Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

  • Protocol number: J2W-MC-PYAB

    A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 in Participants with Mild to Moderate COVID-19 Illness

  • Protocol number: J2X-MC-PYAH

    A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy with Monoclonal Antibodies in Participants with Mild to Moderate COVID-19 Illness (BLAZE-4)

  • Protocol number: JBT101-DM-002

    DETERMINE

  • Protocol number: JENAVALVE-AR-NCT02732704

    JenaValve Pericardial TAVR Aortic Regurgitation Study

  • Protocol number: JENAVALVE-AS-NCT02732691

    JenaValve Pericardial TAVR System Aortic Stenosis Study

  • Protocol number: JTX-8064-101

    Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

  • Protocol number: JUNO-017004-NCT03331198

    An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

  • Protocol number: KARMET-NCT03781791

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson s Disease-Related Constipation (KARMET)

  • Protocol number: KARMETROLLOVER-NCT04483479

    A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients with Parkinson’s disease and Constipation over a 14-week Period.

  • Protocol number: KCP-9274-901-NCT02702492

    A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

  • Protocol number: KD025-209

    A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis

  • Protocol number: KETORLACVSCORTICOSTEROID

    Comparing Intraarticular Ketorolac Versus Corticosteroid in Shoulder Adhesive Capsulitis: A triple-blinded randomized controlled trial

  • Protocol number: KETOROLAC

    Effect of Ketorolac Administration on Postoperative Narcotic Utilization and Union Rates in Great Toe Arthrodesis

  • Protocol number: KEYNOTE-992-NCT04241185

    A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

  • Protocol number: KINIKSA-NCT0000000

    An Open-Label Pilot Study of KPL-914 in Symptomatic Recurrent Idiopathic Pericarditis

  • Protocol number: KRASG12C

    A retrospective cohort study of patient characteristics and treatment outcomes among patients with KRAS G12C mutated non-small cell lung cancer in the Academic Thoracic Oncology Medical Investigator s Consortium (ATOMIC)

  • Protocol number: LAIJ-NCT03670810

    Protocol H8H-MC-LAIJ(a) Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks

  • Protocol number: LATHAMFUND

    Interpreting Glycemic Control in People with Type 2 Diabetes and Chronic Kidney Disease

  • Protocol number: LEANORA

    evaLuation of variations pharmacokinEtics and phArmacogeNOmics of Ribociclib in rAce-based Cohorts: The LEANORA study

  • Protocol number: LEARN-NCT02488720

    Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial

  • Protocol number: LEVA

    Study of Home-Based Pelvic Muscle Training for Survivors of Gynecologic Cancer

  • Protocol number: LIFE-BTK

    LIFE-BTK (pivotaL Investigation of saFety and Efficacy of BRS Treatment-Below The Knee) Randomized Controlled Trial

  • Protocol number: LIMB-ISCHEMIA

    Prospective Study Evaluating the Effect of Skin Pigmentation on Clinical Exam for Determination of Limb Ischemia in Patients with Digital Injuries

  • Protocol number: LIST

    A prospective pilot study to assess for histologic changes on vulvar biopsies in postmenopausal women with Lichen Sclerosus treated with Fractionated CO2 Laser therapy

  • Protocol number: LITERACY

    Limited Health Literacy in Patients with Rotator Cuff Tears: Risk Factors and Outcome Effects

  • Protocol number: LOWRISKTAVR-NCT02628899

    Feasibilty of Transcatheter Aortic Valve Replacement in Low-Risk Patients with Symptomatic, Severe Aortic Stenosis

  • Protocol number: LOWRISKTAVR2-NCT03557242

    Strategies to prevent transcatheter heart valve dysfunction in low risk transcatheter aortic valve replacement

  • Protocol number: LU002

    Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

  • Protocol number: LUN18-335-NCT03909334

    An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC

  • Protocol number: LUNAR-EF-24

    LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure

  • Protocol number: LUNGPACER

    A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning from Mechanical Ventilation in ICU Patients (RESCUE 3)

  • Protocol number: LUNGULTRASOUND-SMOKE

    Use of Philips Lumify Point-of-Care Handheld Ultrasound to Identify Smoke Inhalation Lung Injury.

  • Protocol number: LVADCANNULA

    LVAD Cannula Study: Evaluation of the Anatomic Relationship of Inflow and Outflow Cannula to Flow Dynamics and Clinical Outcomes in Patients with Left Ventricular Assist Devices

  • Protocol number: M15-736

    A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

  • Protocol number: M20-310

    ibrutiNib in SARS CoV-2 induced Pulmonary Injury and Respiratory failure (iNSPIRE)

  • Protocol number: M6-CPAS-NCT04122248

    M6-C™ Artificial Cervical Disc IDE Post-Approval Study

  • Protocol number: MAC2V3

    Multicenter randomized pragmatic clinical trial comparing twoversus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease

  • Protocol number: MARCH

    Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis

  • Protocol number: MATCH-STUDY

    Measurements of AV Access Blood Flow with the Alio Medical Remote Monitoring System to Determine Maturation Status and Patency in ESRD Patients

  • Protocol number: MCLA-128-CL01-NCT02912949

    A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

  • Protocol number: MEDIWOUNDNEXT-NCT04040660

    Use of NexoBrid for Treatment of Acute deep partial and full thickness Burn Injuries

  • Protocol number: MEL17-309-NCT03528408

    Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma

  • Protocol number: MERCK-MK-8591

    A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection

  • Protocol number: MIG-IDN

    A prospective observational study assessing the burden of migraine in an Integrated Delivery Network (IDN) setting

  • Protocol number: MITRAL2-NCT04408430

    The safety and effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra valve with Commander delivery system in patients with symptomatic severe calcific mitral valve disease with severe mitral annular calcification who are not candidates for standard mitral valve surgery.

  • Protocol number: MK-3475-587

    A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

  • Protocol number: MK-3475-B61-NCT04704219

    A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)

  • Protocol number: MK-3475-U01-NCT04165798

    A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

  • Protocol number: MK-6482-011

    An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy

  • Protocol number: MK-6482-013

    Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma

  • Protocol number: MK-8591A-017

    A Phase 3, Randomized, Active-Controlled, Open-label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy

  • Protocol number: MK-8591A-019

    A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL

  • Protocol number: MK3475-365-NCT02861573

    Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

  • Protocol number: MK3475-587

    A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

  • Protocol number: MK3475-866-00

    A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866)

  • Protocol number: MK3475-905-NCT03924895

    A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Cisplatin-Ineligible Participants With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)

  • Protocol number: MK3475-U01-NCT04165798

    Master: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

  • Protocol number: MK7339-001-GOG3036

    A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)

  • Protocol number: MK7339-013

    A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  • Protocol number: MK7902-017

    A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment

  • Protocol number: ML41591-NCT04302025

    Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients With Stages I-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, or BRAF v600E Molecular Alterations

  • Protocol number: ML42919

    A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab with Atezolizumab plus Bevacizumab in Previously-Treated Advanced Non- squamous NSCLC

  • Protocol number: MOMENTUMCAP-NCT02892955

    MOMENTUM 3: Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3

  • Protocol number: MRNA-4157-P201-NCT03897881

    A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)

  • Protocol number: MRX-EAP

    An Expanded-Access Program for Maralixibat in Patients with Cholestatic Pruritis Associated with Alagile Syndrome

  • Protocol number: MS-PCSH

    A Pilot Research Study to Evaluate the Impact of a Patient-Centered Specialty Home Model of Care to Treat and Manage Multiple Sclerosis Patients

  • Protocol number: MS200095-0031

    A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)

  • Protocol number: NAPOLI-2-NCT04005339

    Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2)

  • Protocol number: NBI-98854-HD3005

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington s Disease

  • Protocol number: NBI-98854-HD3006

    Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntington Disease

  • Protocol number: NCT01442194

    Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy

  • Protocol number: NCT01524276

    Product Surveillance Registry Base Protocol

  • Protocol number: NCT01574053

    Enroll-HD: A Prospective Registry Study in a Global Huntington’s Disease Cohort A CHDI Foundation Project

  • Protocol number: NCT01629043

    NATIONAL PARKINSON FOUNDATION PATIENT REGISTRY

  • Protocol number: NCT01892345

    A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial To Evaluate The Safety And Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)

  • Protocol number: NCT02242487

    A 12-Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena)

  • Protocol number: NCT02350465

    The Age-Related Muscle Function Study – Phase II

  • Protocol number: NCT02397096

    A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

  • Protocol number: NCT02403674

    A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects

  • Protocol number: NCT02489617-TBCRC034

    The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy

  • Protocol number: NCT02542696

    An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF”Episodes)

  • Protocol number: NCT02654587-OSE2101C301

    A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small-Cell Lung Cancer With Progressive Disease After Last Treatment With Immune Checkpoint Inhibitors (ICI). (OSE2101C301)

  • Protocol number: NCT02707861

    A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1

  • Protocol number: NCT02741323

    Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

  • Protocol number: NCT02956382-2016-0014

    Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

  • Protocol number: NCT03209401-2017-0085

    Niraparib Plus Carboplatin in Patients with Homologous Recombination Deficient Advanced Solid Tumor Malignancies

  • Protocol number: NCT03467867-2017-1502

    A Phase II Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

  • Protocol number: NCT03555955-STUDY00000226

    A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients with Hematologic Malignancies

  • Protocol number: NEKTAR-20-214-29

    A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

  • Protocol number: NEUROCOGNITION

    Rate of Neurocognitive Decline in Adults with Sickle Cell Disease: an institutional Study

  • Protocol number: NGM18-0402-BZA53730-NCT0406889

    A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

  • Protocol number: NIC-NCT02720445

    Long Term Nicotine Treatment of Mild Cognitive Impairment

  • Protocol number: NLY01PD1-NCT04154072

    Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease

  • Protocol number: NOD

    Clinical Investigation of Inflammatory Bowel Diseases, Intestinal Failure and Transplantation

  • Protocol number: NRG-BR007-NCT04852887

    A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE </= 18 BREAST CANCER

  • Protocol number: NRG-CC003

    RANDOMIZED PHASE II/III TRIAL OF PROPHYLACTIC CRANIAL IRRADIATION WITH OR WITHOUT HIPPOCAMPAL AVOIDANCE FOR SMALL CELL LUNG CANCER

  • Protocol number: NRG-CC007CD-NCT03860961

    Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy

  • Protocol number: NRG-CC009

    PHASE III TRIAL OF STEREOTACTIC RADIOSURGERY (SRS) VERSUS HIPPOCAMPAL-AVOIDANT WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR 10 OR FEWER BRAIN METASTASES FROM SMALL CELL LUNG CANCER

  • Protocol number: NRG-GY018-NCT03914612

    A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

  • Protocol number: NTX20201

    A Phase 2a, Multicenter, Randomized, Patient and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Acute Single Transected Peripheral Nerve Injury Occurring below the Distal Border of the Brachial Plexus Requiring Surgical Repair.

  • Protocol number: OASIS-NCT04720664

    A Phase II Trial of SM-88 in Patients with Metastatic Hormone Receptor-Positive and HER2-Negative (HR+/HER2-) Breast Cancer

  • Protocol number: OCARINA-I-NCT03972306

    A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SUBCUTANEOUS OCRELIZUMAB ADMINISTRATION IN PATIENTS WITH MULTIPLE SCLEROSIS

  • Protocol number: ODYSSEY-FSH

    A randomized, double-blind, placebo-controlled study with open label option to investigate the efficacy of tradipitant in treating inflammatory lung injury and improving clinical outcomes associated with severe COVID-19 infection

  • Protocol number: ODYSSEY-GSH

    A randomized, double-blind, placebo-controlled study with open label option to investigate the efficacy of tradipitant in treating inflammatory lung injury and improving clinical outcomes associated with severe COVID-19 infection

  • Protocol number: ODYSSEY-UMH

    A randomized, double-blind, placebo-controlled study with open label option to investigate the efficacy of tradipitant in treating inflammatory lung injury and improving clinical outcomes associated with severe COVID-19 infection

  • Protocol number: ODYSSEY-WHC

    A randomized, double-blind, placebo-controlled study with open label option to investigate the efficacy of tradipitant in treating inflammatory lung injury and improving clinical outcomes associated with severe COVID-19 infection

  • Protocol number: OHAND-NCT04035005

    A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

  • Protocol number: OKRA-NCT03326076

    Evaluation of Patient Outcomes from the Kidney Allograft Outcomes Allosure Registry (KOAR) - Amendment 1 - OKRA

  • Protocol number: OLIX

    Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery

  • Protocol number: ON-Q-PUMP

    The impact of the continuous infusion of intraperitoneal analgesics on postoperative pain after minimally invasive hysterectomy: a randomized controlled trial

  • Protocol number: ONWARD

    A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with noninsulinanti-diabetic treatment, in insulin naïve subjects with type 2 diabetes.

  • Protocol number: ONWARD4

    A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with bolus insulin with or without non-insulin anti-diabetic drugs, in subjects with type 2 diabetes on a basal-bolus regimen.

  • Protocol number: ONWARDS-5

    Effectiveness and safety of once weekly insulin icodec used with DoseGuide versus once daily basal insulin analogues in an insulin naïve type 2 diabetes population in a clinical practice setting

  • Protocol number: OPTIMIZEPRO-NCT04091048

    Optimize PRO Study

  • Protocol number: OPTION-NCT03795298

    Comparison of Anticoagulation with Left Atrial Appendage Closure after AF Ablation

  • Protocol number: ORTHOSPACE-NCT02493660

    A Study to Assess the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears

  • Protocol number: PAC-203

    Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib

  • Protocol number: PACER

    A Phase II Study of electron beam intraoperative radiation therapy following chemoradiation in patients with pancreatic cancer with vascular involvement

  • Protocol number: PACIFIC4-FSQ

    A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

  • Protocol number: PAI-CARE

    Personalized Artificial Intelligence Wellness Assistants for patients with Heart Failure (PAI Care)

  • Protocol number: PALBODCIS-NCT03535506

    Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery

  • Protocol number: PANCDX

    Pancreas and Renal Rejection Diagnosis Using Circulating Donor-Derived Cell-free DNA in Peripheral Blood (PANCDx)

  • Protocol number: PANFLUID-REF

    PANCREATIC CYSTIC FLUID REFERENCE SET

  • Protocol number: PARADIGHM-NCT01922440

    A Registry for Patients With Chronic Hypoparathyroidism (PARADIGHM)

  • Protocol number: PARTNERII-PAS

    PARTNER II Post Approval Study Plan

  • Protocol number: PDDUAL-NCT03402009

    Evaluation of oral anti-parkinsonian medication use in patients with advanced Parkinson s disease with history of Deep Brain Stimulation (DBS) and being treated with Carbidopa Levodopa Enteral Suspension (CLES)

  • Protocol number: PDY16894

    A multicenter, Phase 2a, open-label, non-randomized study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with persistent/chronic immune thrombocytopenia (ITP)

  • Protocol number: PERFORMANCEII-NCT04201132

    Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery system comprised oF a pOst-dilation balloon, integrated eMbolic filter, and A Novel Carotid stEnt II

  • Protocol number: PGX-ACT

    Pharmacogenomics (PGx) Applied to Chronic pain Treatment in primary care (PGx-ACT)

  • Protocol number: PHASEBIO

    A Phase 3, Multicenter, Open-Label, Single-Arm Study of PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure.

  • Protocol number: PICO

    PICO single-use Negative Pressure Wound Therapy System

  • Protocol number: PL101-HD301

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease

  • Protocol number: POLYNOVO-NCT04090424

    A Pivotal Study to Assess the Safety and Effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries.

  • Protocol number: PORTICO-NCT02000115

    PorticoTM Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO)

  • Protocol number: PORTICONG-NCT04011722

    Evaluation of the Portico™ NG Transcatheter Aortic Valve in High and Extreme Risk Patients with Symptomatic Severe Aortic Stenosis (Portico NG Approval Study)

  • Protocol number: PRAECIS-NCT03815110

    Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Factor (sFlt-1/PlGF) to Stratify Risk in Pregnant Women with Hypertensive Disorders of Pregnancy

  • Protocol number: PRESERVE-NCT02381509

    Predicting the Safety and Effectiveness of Inferior Vena Cava Filters

  • Protocol number: PROACTIVE

    The Prospera Kidney Transplant Active Rejection Assessment Registry

  • Protocol number: PROGO-USWM-SA1-4001

    A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and other Clinical Outcome Assessments of Parkinson s Disease Patients Treated with XADAGO (safinamide) Tablets

  • Protocol number: PROGRESS-NCT03777059

    A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PROGRESS)

  • Protocol number: PROTECTEDTAVR-NCT04149535

    PROTECTED TAVR: Stroke PROTECTion with SEntinel During Transcatheter Aortic Valve Replacement

  • Protocol number: PROTON-PANC-NCT03885284

    Phase I Study of Proton Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC)

  • Protocol number: PRS-343-PCS0416-NCT033305

    A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

  • Protocol number: PSR-APV

    Aortic, Peripheral & Venous (APV) Product Surveillance Registry Platform Base

  • Protocol number: PULSED-AF

    Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF (PULSED AF)

  • Protocol number: QBGJ398-302-NCT04197986

    Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)

  • Protocol number: R5093-ONC-1863-NCT04077099

    A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

  • Protocol number: RADCOMP-NCT02603341

    Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

  • Protocol number: RAPA-501-ALLO

    Donation of Blood Lymphocytes for Manufacturing of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for Post-Intubation Stage 3 COVID-19 Disease

  • Protocol number: RECELL-BIOPSY

    Evaluation of Healing Following Use of the RECELL® Device for Treatment of Acute Thermal Burns

  • Protocol number: RECELL-SOFTTISSUE

    A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of the RECELL® System Combined with Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction

  • Protocol number: RECON-NCT01809002

    Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair (RECON)

  • Protocol number: REDWOOD-NCT04095793

    A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD&#727;9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

  • Protocol number: REFALS-ES-NCT03948178

    EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS: OPEN-LABEL EXTENSION FOR PATIENTS COMPLETING STUDY 3119002

  • Protocol number: RELAYPRO-NCT03033043

    Study of RelayPro Thoracic Stent-Graft in Subjects With Acute, Complicated Type B Aortic Dissection

  • Protocol number: RENOVACARE

    An Open Label Pilot Study to Evaluate the CellMist™ System in the Treatment of Deep Second Degree (IIºB) Burn Injuries with Autologous Skin Cells.

  • Protocol number: RESSOM

    Establishment of a Liver Tissue Bank

  • Protocol number: RESTORE-NCT02586623

    RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy

  • Protocol number: RETRO

    A2/A2B to B Transplantation Reduces Disparities in Transplant Access While Maintaining Current Levels of Graft and Patient Survival

  • Protocol number: RETROCLK

    Retrospective study to analyze patient and transplant outcomes in recipients of combined Liver and Kidney Transplant (CLK) at the Medstar Georgetown University Hospital (MGUH)

  • Protocol number: RISE-NCT04729751

    Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome

  • Protocol number: ROCHE-BN40423

    A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE

  • Protocol number: ROCHE-NATURALHISTORY

    A multi-site, prospective, longitudinal, cohort study measuring cerebrospinal fluid mutant-huntingtin protein in patients with Huntington's Disease

  • Protocol number: RPNI

    Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation: A Randomized, Prospective Study

  • Protocol number: S1609-NCT02834013

    DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

  • Protocol number: S1801-NCT03698019

    A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma

  • Protocol number: S1826-NCT03907488

    A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

  • Protocol number: SAG2424

    Psychometric Validation Study for the Huntington’s Disease Everyday Functioning (Hi-DEF) Scale

  • Protocol number: SARS-COV-2-STUDY00003531

    Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL

  • Protocol number: SAS-US-SPN-17-11267

    A prospective, multi-center, observational study of the safety, tolerability and effectiveness of SPINRAZA&#61666; in adult patients with Spinal Muscular Atrophy

  • Protocol number: SAVISCOUT

    SAVI SCOUT® System for Excision of nonpalpable breast lesions: Single institutional study regarding experiences, lessons learned & comparisons to needle localization

  • Protocol number: SBS-NCT01990040

    A Prospective, Multi-center Registry for Patients with Short Bowel Syndrome

  • Protocol number: SECURE

    A ProSpective, MulticEnter, Concurrently Controlled Clinical Study of Chondro-Gide® ArticUlar Cartilage CoveR for the Treatment of Large Chondral Lesions in the KnEe (SECURE)

  • Protocol number: SELECT-NCT03574597

    Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

  • Protocol number: SGN22E-002-NCT03288545

    A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer

  • Protocol number: SGN22E-003

    An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

  • Protocol number: SGNTUC-016-NCT03975647

    Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)

  • Protocol number: SGNTUC-019-NCT04579380

    A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

  • Protocol number: SGNTUC-022-NCT04499924

    A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

  • Protocol number: SGNTUC-025-NCT04539938

    A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer

  • Protocol number: SHORE-NCT03695601

    SURVEILLANCE HEARTCARE® OUTCOMES REGISTRY (SHORE)

  • Protocol number: SJS-TENS

    Comprehensive Genomic Analysis of Adverse Vaccine and Cutaneous Adverse Drug Reactions

  • Protocol number: SMA-CHART-REVIEW-NCT99999999

    Emerging Real-World Use of Nusinersen in Adult Patients with Spinal Muscular Atrophy (SMA) in the US: A Multi-Site Chart Review Study

  • Protocol number: SMART-TRIAL

    SMall Annuli Randomized To Evolut or SAPIEN Trial (SMART Trial)

  • Protocol number: SNS-301-2-2NCT04034225

    An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck

  • Protocol number: SPECTRAL2

    DeepView SnapShot Portable (DV-SSP): Device Training Study

  • Protocol number: SPI-POZ-202-NCT03318939

    A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

  • Protocol number: SPINALSINGULARITY-NCT04059159

    ES-NIH-01: Clinical Evaluation of the Connected Catheter Wireless Urinary Prosthesis for Management of chronic Urinary Retention

  • Protocol number: SPLIT

    Prospective Observational Study to Assess Outcomes in Pediatric Liver Transplant Recipients

  • Protocol number: SS-CARDIO

    Stress, Sleep and Cardiovascular Risk

  • Protocol number: STELLAR-NCT03683030

    Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (STELLAR)

  • Protocol number: STRATAECR

    Scarring in Stratagraft-treated vs. autograft-treated burn wounds: a clinical and histological investigation

  • Protocol number: STRATASOMA

    A Phase 1/2a, Controlled, Randomized, Multicenter Study Evaluating the Efficacy, Safety, Tolerability of StrataGraft Skin Tissue Overlay of Meshed Autograft (SOMA) in Treatment of Full-Thickness Thermal Burns

  • Protocol number: STUDY00000017

    A randomized, double blind, placebo-controlled study to evaluate the impact of Bosutinib on safety, tolerability, biomarkers and clinical outcomes in Dementia with Lewy Bodies (DLB)

  • Protocol number: STUDY00000122

    A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)

  • Protocol number: STUDY00000176-NCT03939689

    A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen (PSMA)-Avid, Chemotherapy-naive, and Progressed on Abiraterone

  • Protocol number: STUDY00000266

    A randomized, double blind, placebo-controlled study to evaluate the impact of K0706 on safety, tolerability, pharmacokinetics and pharmacodynamics and clinical outcomes in Dementia with Lewy Bodies (DLB).

  • Protocol number: STUDY00000313

    Characteristics of mercury vapor poisoning

  • Protocol number: STUDY00000327

    Using Single Cell Transcriptomics to Understand Tumor and Immune Heterogeneity Driving Resistance and to Rationally Select Immune Therapy in Advanced RCC

  • Protocol number: STUDY00000474

    Mobile Text Messaging Intervention for Indoor Tanning Addiction

  • Protocol number: STUDY00000501

    Chronic Stress, QOL, and Physical Activity among Breast Cancer Survivors

  • Protocol number: STUDY00000665-NCT03761563

    Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects with Degenerative Disc Disease (FORTE)

  • Protocol number: STUDY00000805

    Biomarkers to Evaluate Immune Related Adverse Events (irAEs) Due to Treatment with Immune Checkpoint Inhibitors (ICIs)

  • Protocol number: STUDY00001001MEDLEY

    A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)

  • Protocol number: STUDY00001007

    Peer Support For Young Adult Women With High Breast Cancer Risk

  • Protocol number: STUDY00001073

    Streamlined Genetic Testing in Prostate Cancer

  • Protocol number: STUDY00001078-NCT03974711

    The Rampart Duo Clinical (RaDical) Study

  • Protocol number: STUDY00001137

    Parent Communication Study IV: Improving Genetic Counseling for BRCA+ Mothers

  • Protocol number: STUDY00001323-NCT04012996

    A Multi-Center, Prospective, Randomized Controlled Trial Comparing the Safety and Effectiveness of prodisc C SK and prodisc C Vivo to Mobi-C Cervical Disc in the Treatment of Two-Level Symptomatic Cervical Disc Disease

  • Protocol number: STUDY00001383

    Breast Imaging Education in Radiology Residency

  • Protocol number: STUDY00001487-TBCRC047

    Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

  • Protocol number: STUDY00001657-NCT04064411

    A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)

  • Protocol number: STUDY00001708

    Barriers and Facilitators to Screening

  • Protocol number: STUDY00001840-NCT04294004

    A proSpecTive, Randomized, controlled, single-blind, dose-finding, mUlti-Center, parallel group study of the safeTy and efficacy of KUR-113 Bone Graft (TGplPTH1-34 in fibrin) versus local autograft for the treatment of patients undergoing single-level transforaminal lumbar intErbody fusion (the STRUCTURE study)

  • Protocol number: STUDY00001920

    Programa de ARBOLES Familiares: Assessing Risk of Breast Cancer through Outreach to Latinas with Education and Support

  • Protocol number: STUDY00002130

    A Multicenter Case-Control Study of the Efficacy of EsoGuard&#63195; on Samples Collected Using EsoCheck&#63195;, versus Esophagogastroduodenoscopy, for the Diagnosis of Barrett s Esophagus with and without Dysplasia, and for Esophageal Adenocarcinoma

  • Protocol number: STUDY00002424

    Investigating Exposure to Endocrine Disrupting Chemicals and Poor Sleep in Breast Cancer Survivors

  • Protocol number: STUDY00002478

    Exploring Provider Referral Patterns for Supplemental Breast Screening

  • Protocol number: STUDY00002708

    Testing Methods to Increase Lung Cancer Screening Among Quitline Callers

  • Protocol number: STUDY00002789

    Informing Latinas about HBOC risk: a Randomized Controlled Trial

  • Protocol number: STUDY00002895

    Acupressure Intervention to Improve Chemotherapy-related Side Effects and Functioning of Patients with Gastrointestinal Cancers

  • Protocol number: STUDY00002978

    Genetic Screening for Adult-Onset Inherited Cancer Syndromes in Minors: Policy Implications

  • Protocol number: STUDY00003033-NCT03524118

    A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants

  • Protocol number: STUDY00003073-NCT03820947

    Medtronic VenaSeal Spectrum: Global, Post-Market Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease

  • Protocol number: STUDY00003267

    Families SHARE

  • Protocol number: STUDY00003351

    Diet and Cancer-Related Symptoms

  • Protocol number: STUDY00003425

    Liquid Embolization of Arterial Hemorrhages in the Peripheral Vasculature The LAVA Study

  • Protocol number: STUDY00003772

    Understanding HPV Vaccination Behavior to Prevent Cancer

  • Protocol number: STUDY00003967

    Educating Providers about Lung Screening

  • Protocol number: SUMMIT-NCT03433274

    Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

  • Protocol number: SUN-PRO00038942

    Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow

  • Protocol number: TALAPRO-3-MWHC

    TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

  • Protocol number: TALAVE-WI236547

    TALAVE: A Pilot Trial of Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

  • Protocol number: TARGET-HCC-NCT02954094

    A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma

  • Protocol number: TARGET-HCV-AM5-NCT01474811

    Target HCV AM 5:Hepatitis C Therapeutic Registry and Research Network-­A Longitudinal, Observational Study

  • Protocol number: TARGET-NASH-NCT02815891

    A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis

  • Protocol number: TAVRUNLOAD-NCT02661451

    Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure: a randomized trial (TAVR UNLOAD)

  • Protocol number: TBCRC-052

    MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer

  • Protocol number: TBCRC037-NCT02206984

    A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer

  • Protocol number: TBCRC044-NCT03095352

    A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

  • Protocol number: TBCRC045-NCT03414658

    A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab

  • Protocol number: TBCRC051-NCT03941730

    THERAPEUTIC TARGETING OF ER BETA IN TRIPLE NEGATIVE BREAST CANCER

  • Protocol number: TBCRCREPOSITORY

    Biospecimen and Outcomes Repository

  • Protocol number: TEASER-NCT02540109

    Targeted Transcranial Electrotherapy to Accelerate Stroke Rehabilitation-Exploratory Trial on Aphasia

  • Protocol number: THUMB-CMC

    Prospective Longitudinal Study of Non-Operative and Operative Thumb CMC Arthritis Interventions

  • Protocol number: TJ003234COV201

    A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects with Severe Coronavirus Disease 2019 (COVID-19)

  • Protocol number: TNT009-201-NCT03275454

    THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS & PHARMACODYNAMICS OF MULTIPLE-DOSE TNT009 IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

  • Protocol number: TORUS2-NCT04130737

    The PQ Bypass pivOtal IDE intra-aRterial stent graft study for occlUsive and re-Stenotic fem-pop revascularization 2 Trial: TORUS 2

  • Protocol number: TPX-0005-01-NCT03093116

    A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

  • Protocol number: TPX-0046-01

    A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations

  • Protocol number: TRANSMURAL-NCT03432494

    Early feasibility evaluation of Transmural Systems Transcaval Closure Device (TCD) for transcaval access ports during transcatheter aortic valve replacement (TAVR)

  • Protocol number: TREATMS-NCT03500328

    TRADITIONAL VERSUS EARLY AGGRESSIVE THERAPY FOR MULTIPLE SCLEROSIS (TREAT-MS) TRIAL

  • Protocol number: TREO-PAS

    Post-Approval Study of the TREO Abdominal Stent- Graft System (P190015) in Patients with Infrarenal Abdominal Aortic and Aorto-iliac Aneurysms

  • Protocol number: TRILUMINATE-NCT03904147

    Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal

  • Protocol number: TRIUMPH-NCT99999999

    Protocol I5Q-MC-B004: preventive TReatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems (TRIUMPH)

  • Protocol number: TRULO-NCT04491552

    TruGraf Long-term Clinical Outcomes Study

  • Protocol number: TTI-622-01-NCT03530683

    A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma

  • Protocol number: TUMORCOLLAGEN

    Tumor Associated Collagen Signature in Hepatocellular Carcinoma

  • Protocol number: TYR-219-01-NCT04474470

    A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced solid tumors and Head and Neck cancer

  • Protocol number: UCLAHCCRETRO

    Multi-Institutional Validation of A Novel Prognostic Nomogram Predicting Hepatocellular Carcinoma Recurrence after Liver Transplantation

  • Protocol number: UPIT

    Unleash the Potential of Intestinal Transplant

  • Protocol number: VASCADEMVP-NCT04203329

    A Multi-center, Prospective, Single Arm Registry to Evaluate Procedural Outcomes Using the Cardiva VASCADE MVP VVCS Closure Device After Catheter-based Atrial Fibrillation Interventions for Patients Who Are Discharged the Same Day.

  • Protocol number: VERILY-NCT04905459

    A multicenter study to evaluate the performance of Automated Retinal Disease Assessment software for the detection of more than mild Diabetic Retinopathy (ARDA mtmDR study)

  • Protocol number: VESPER-VIVID

    Venous stent for the Iliofemoral Vein Investigational clinical trial using the DUO™ Venous Stent System (VIVID)

  • Protocol number: VIIV

    A multi- site observational study to assess safety and effectiveness of prenatal exposure to Dolutegravir in HIV positive pregnant women

  • Protocol number: VISUAL-HEARTFAIL

    Patient Visualization of Personalized Cardiac Imaging to Improve Health Literacy and Medication Adherence in Patients with Heart Failure

  • Protocol number: VS-6766-NCT04620330

    A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

  • Protocol number: VYR-VSV2-203-NCT04291105

    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma

  • Protocol number: WATS-NCT02988934

    The WATS3-D (Wide Area Transepithelial Sample Biopsy with 3-Dimensional Computer-Assisted Analysis) U.S. Registry

  • Protocol number: WF-1803CD-NCT03746314

    Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices (NCORP)

  • Protocol number: WN39658

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Early (prodromal to mild) Alzheimer's Disease

  • Protocol number: WO39608-NCT03193190

    A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

  • Protocol number: XL184-021-NCT03170960

    A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

  • Protocol number: Z11102

    Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)

  • Protocol number: ZAMBON-NCT03460704

    A Double-Blind, Placebo Controlled, Multi-Centre, Clinical Trial to Investigate the Efficacy and Safety of 24 months of Therapy with Inhaled Colistimethate Sodium in the Treatment of Subjects with Non-Cystic Fibrosis Bronchiectasis Chronically Infected with Pseudomonas Aeruginosa (P.Aeruginosa)

  • Protocol number: ZIMMER-SUBCHONDROPLASTY

    A Randomized Controlled Trial of the Subchondroplasty® Procedure with Arthroscopy versus Arthroscopy Alone for Treatment of Bone Marrow Lesions in the Knee

  • Protocol number: ZYGOOD-NCT04000867

    Treatment for Foot Pain Caused by Diabetic Neuropathy Using Recurrent TransCutaneous Magnetic Stimulation (TCMS)

All clinical trials

Our trials are carefully planned research studies that have led to important discoveries such as new drugs, procedures, and diagnostic approaches that make our lives better.

Volunteering in our trial offers potential benefits, including:

  • The opportunity to become involved in the testing of a new drug that may have potential to improve your condition

  • Close contact with the study team for management of your disease

  • Contributing to medical science, which may help others now and in the future

Frequently asked questions

  • Q: Why volunteer?

    A: Does volunteering for a clinical trial make sense for you? The following information will help you to decide.

  • Q: What are clinical trials and why are they important?

    A: Clinical trials are carefully planned research studies that have led to important discoveries such as new drugs, devices, procedures, biologics, and diagnostic approaches. These new discoveries make our lives better such as new medicines to treat cancer, diabetes, and other diseases. Some other words for clinical trials are research, survey, or experiment.

    Know what you are getting into and don’t be afraid to ask questions. A clinical trial may or may not help you personally. The results from the study could help others who have a health problem. Taking part in research is voluntary. It is your decision!

  • Q: Why do we need clinical trials?

    A: A series of clinical trials for each possible treatment must be done before the Food and Drug Administration (FDA) will approve a drug, procedure, or device. Many of the trials done at MedStar Health Research Institute are trials testing possible drugs or devices. A drug must be shown to be safe and useful for public use before the FDA can approve it.

    From the lab bench to the drug store, developing a new drug is a long and expensive process. It is estimated to take about 10 years and $800 million to bring one new drug to market (R & D Directions, January 2002).

  • Q: Are clinical trials safe?

    A: Protections have been put in place to safeguard your rights, safety, and privacy in research. Many layers of oversight include an institutional review board (ethical review board), the Food and Drug Administration (FDA), and periodic monitoring of study data by independent experts, patient advocates, community advisory board members, and community partners.

    • Screening trials test the best way to detect certain diseases or health conditions

    • Diagnostic trials determine better tests or procedures for diagnosing a particular disease or condition

    • Treatment trials test new treatments, new combinations of drugs, or new approaches to surgery

    • Quality of life trials explore and measure ways to improve the comfort and quality of life of people with a chronic illness

  • Q: Who can participate in a clinical trial?

    A: People with the condition being studied or healthy people can volunteer to take part in a clinical trial. Each study has specific entry requirements such as age or a medical condition necessary for participation.

    The doctor in charge of the study must review the volunteers' medical history to determine if he/she is eligible to participate based on strict study conditions called entry criteria.

  • Q: Who is in charge of a clinical trial?

    A: A medical doctor is usually responsible for carrying out the study according to the study protocol. Before a clinical trial can begin to enroll volunteers, an Institutional Review Board (IRB) must approve it. The IRB is a committee made up of healthcare experts that review each study to protect patient rights and ensure the safety of research volunteers. The IRB also ensures the research is scientifically sound and is involved in the review of safety issues throughout the study.

  • Q: What is informed consent?

    A: One of the documents the IRB must review and approve is called an Informed Consent Form. This is provided to volunteers who are interested in participating in a clinical trial program. The informed consent includes everything a volunteer needs to know about the study so that he/she can make an informed decision as to whether or not to participate. The process allows volunteers to ask questions. Volunteers are encouraged to take their time in making a decision before signing the consent and joining the study. You and your family should feel completely comfortable with your decision to participate before you sign the consent.

  • Q: What are the benefits to being in a clinical trial?

    A: Once enrolled in a clinical trial, many volunteers find there are a number of potential benefits to participation. These can include:

    • The opportunity to become involved in the testing of a new drug that may have potential to improve your condition.

    • Close contact with the study team for management of your disease.

    • Contributing to medical science, which may help others now and in the future.

    However, volunteers understand that there may not be any benefit to participating in a study.

  • Q: Why do we need diversity in a research?

    A: Race, ethnicity, age, and other factors can affect how people respond to medicine.

  • Q: Why do many still feel uneasy about being part of a clinical trial?

    A: The Tuskegee Syphilis Study and the cancer cells taken from Henrietta Lacks without her knowledge are two reasons for the continued distrust with the African American community. Today, there is low participation in clinical trials from African Americans. We may not know if certain treatments will be effective in this population.

  • Q: Will my health insurance pay for a clinical trial?

    A: Federal law requires insurance companies to cover routine costs, which are things you need regardless of a clinical trial. If the study sponsor requires extra testing, they will typically cover the cost.

  • Q: Can I drop out of a clinical trial and still receive quality care?

    A: You are in control. If you decide you do not want to participate anymore, you can withdraw at any time. You will receive the same high-quality care at MedStar Health. Your clinical team may ask to continue monitoring you for a period of time to assess effects of the treatment you have already received.

  • Q: Are clinical trials considered a last-ditch effort for patients?

    Phases of Clinical Research

    A: Not true at all! Clinical trials allow access to treatments that are up and coming but not yet available to the general population.

  • Q: Interested in participating in a clinical trial by MedStar Health?

    A: Email JoinResearch@MedStar.net or call 833-998-0900 (toll-free) to learn more and ask about our open studies.